Epizyme Inc.

Plus: Woodcock, Kim join Friends of Cancer Research’s board and updates from Recursion, Medtronic and more

The enzyme target represents a synthetic lethal precision medicine opportunity for 15% of all human cancers

Patients aren’t getting the targeted therapy they need because they’re not being diagnosed

ATP-backed biotech gets $45M up front for pair of molecules derived from STAR platform, extending runway with first-in-human trial due this year

3Q22 Financial Markets Preview: As pain grinds on, signals that biotech may be on road to recovery

Budget-priced $247M acquisition of epigenetics pioneer with slow-selling drug could deliver more value to Epizyme’s shareholders via CVR

Plus Ramanan joins Turnstone as CFO, updates from Camp4, ImmPact, Akoya and more

Plus Dias becomes CMO at Coherus, updates from Illumina, Metagenomi, Adrenomed, Epizyme, Garuda and more

Plus Karyopharm tumbles, Epizyme cuts, and updates from Alnylam, Novavax, Gilead and more

Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more